Back to Trades
Total Value
$458.9K
Net $226.9K sold
Filing Date
Sep 25, 2025
3 transactions
Sales
$226.9K
3 transactions
Trade Summary
On Sep 23, 2025 through Sep 25, 2025, AULT MILTON C III, Insider, sold $458.9K of Alzamend Neuro, Inc. (ALZN) across 3 transactions. The filing covers Common Stock and reflects net selling of $226.9K. Reported prices ranged from $2.31 to $2.38. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- Alzamend Neuro, Inc.
- Ticker Symbol
- ALZN
- CIK
- 0001677077
Insider Information
- Role
- Insider
- Location
- LAS VEGAS, NV
Filing Details
- Filing Date
- Sep 25, 2025
- Transaction Date
- Sep 23, 2025
- Accession Number
- 0001214659-25-014210
- Form Type
- 4
- Net Trading Amount
- -$226.9K
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Sep 23, 2025 | Common Stock | 43,238 | $2.38 | Sale | $102.7K |
| Sep 24, 2025 | Common Stock | 39,140 | $2.31 | Sale | $90.4K |
| Sep 25, 2025 | Common Stock | 14,628 | $2.31 | Sale | $33.8K |
| Sep 25, 2025 | Common Stock | 100,000 | $2.32 | C | $232.0K |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Sep 25, 2025 | ALZN derivative | 232 | — | C | — |
Want live alerts when AULT MILTON C III trades again?
Download Insider Trades to track ALZN, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)Ault Lending, LLC ("Ault Lending"), is a wholly-owned subsidiary of Hyperscale Data, Inc. ("HSD"). Mr. Ault, the Executive Chairman of HSD, is deemed to have voting and investment power with respect to the securities held of record by Ault Lending.
- (F2)The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sale price of $2.3090. The range of sales prices on the transaction date was $2.3088 to $2.3217 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.
- (F3)Represents shares of common stock received upon conversion of Series B convertible preferred stock ("Series B Preferred").
- (F4)Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences, Inc.
- (F5)Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences Fund, LLC.
- (F6)The Conversion Price of the Series B Preferred is subject to adjustment as set forth in that certain Designation of Preferences, Rights and Limitations of the Series B Convertible Voting Preferred Stock.
- (F7)The shares of Series B Preferred have no expiration date.